![]() ![]() Ampligen achieved a 100% survival rate - as compared to 100% mortality - at clinically achievable human dosage levels in animal experiments. After a 2002 SARS outbreak in the Guangdong province of southern China caused more than 8,000 cases and more than 800 deaths, the United States' National Institutes of Health contracted studies to evaluate potential treatments for SARS. (NYSE American:AIM) today announced the filing of three provisional patent applications related to its drug candidate Ampligen in the company's efforts toward joining the global health community in the fight against the deadly Wuhan coronavirus that has so far infected approximately 40,000 people and killed almost one thousand, primarily in China.Ĭoronaviruses are a large family of viruses, including the deadly Severe Acute Respiratory Syndrome (SARS). Ampligen® obtained 100% survival rate at clinically achievable human dosage levels for SARS in animal experimentsĪmpligen key to proposed broad-spectrum 'universal' coronavirus vaccine ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |